Practice Tip: Stay Connected During a Disaster
With hurricane season on its way, it makes sense to determine how you’ll stay connected with both patients and family members should a storm befall you. The 2 ways to do this: Secure satellite internet and acquire an internet-based phone system. Of the former, Lisa M. Greene, OD, of Asheville Vision and Wellness, in Asheville, North Carolina, says, “It’s like a generator for the internet, in that if we lose a connection with our regular providers, we can flip the system’s switch and use it.” Read more 

Cognition Therapeutics Reports Geographic Atrophy Drug Candidate Slows Lesion Growth Rate
Cognition Therapeutics, Inc. reports that the results of the futility analysis of its drug zervimesine for adults who have geographic atrophy secondary to dry age-related macular degeneration slowed lesion growth in the first 57 participants who completed at least 6 months of dosing. The Phase 2 MAGNIFY study has enrolled a total of 100 participants, with all completing their final clinic visit this month.

Glaukos Epi-on Crosslinking Therapy Making Its Way Through FDA
Glaukos Corporation announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus. The Prescription Drug User Fee Act goal date for the completion of the FDA’s review of the Epioxa NDA is set for October 20, 2025, according to a press release. This date reflects a standard 10-month review period, which is consistent with the company’s expectations. 

Johnson & Johnson Vision Launches Gen Z Campaign
Johnson & Johnson Vision has launched the “Seen with Acuvue” campaign. Specifically, the campaign encourages Gen Z to showcase their most authentic selves each day with the support and comfort of Acuvue contact lenses. A survey related to the campaign shows that 90% of respondents said having the ability to see themselves and their peers more clearly significantly boosted their confidence. Additionally, 83%, 82%, and 89% said they more easily connect when they see clearly,
that wearing contact lenses makes them feel more confident, and that contact lens comfort is the most important factor when choosing contact lenses, respectively.

Opus Genetics Announces Fast Track Designation for Treatment of Significant Chronic Night Driving Impairment
Opus Genetics received the U.S. Food and Drug Administration’s Fast Track designation for its phentolamine ophthalmic solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients who have photic phenomena.

Seonix Bio Offers Clinical Polygenic Risk Score Testing Service for Glaucoma
Seonix Bio announced the U.S. launch of SightScore, a clinical polygenic risk score testing service for primary open-angle glaucoma. Specifically, SightScore uses a saliva test to identify individuals at high risk for glaucoma, enabling earlier diagnosis, intervention, and more personalized treatment while also identifying low-risk individuals who may benefit from less frequent monitoring, according to a press release. For more information visit seonixbio.com. 

Vision Expo East 2025: First Time Attendees Comprise Almost Half of Attendees
Vision Expo East, which occurred in Orlando, Florida, from February 19 to February 22, 2025, saw an influx of first-time attendees, who made up 44% of all show visitors, according to a press release. Additionally, most hailed from Florida, New York, California, Texas, and New Jersey. OM